

Updated Meta-Analysis Comparing FFR-Guided and Angiographic-Guided Intervention in Patients with Multivessel Coronary Artery Disease

Case Report

Volume 2 Issue 1- 2022

Author Details

Rohan M Prasad^{1*}, Zulfiqar Q Baloch², Robert Gumbita², Zaheer Ahmed³, Heesoo Yoo¹, Adolfo M Salazar¹, Joel Cohn²

¹Department of Internal Medicine, Michigan State University, USA

²Department of Cardiology, Sparrow Hospital, USA

³Department of Accident and Emergency Medicine, Royal Preston Hospital, UK

*Corresponding author

Rohan Madhu Prasad, Department of Internal Medicine, Michigan State University, Michigan, USA

Article History

Received: February 15, 2022 Accepted: March 03, 2022 Published: March 04, 2022

Abstract

A new method to guide Percutaneous Coronary Interventions (PCI) and Coronary Artery Bypass Graft (CABG) interventions are by FFR, which is a measurement of the hemodynamic significance of coronary stenosis. We conducted an updated meta-analysis of all randomized controlled trials from inception to 5 December 2021 to compare studies that included patients who underwent FFR-guided PCI or CABG. The statistical analysis was performed using a random effect model to Calculate Risk Ratios (RR) and Mean Difference (MD) with 95% Confidence Intervals (CI). Five RCTs were included with a total of 2,288 patients and a median weighted follow-up period of 16.6 months. In this meta-analysis with a small sample size, there was no difference between FFR-guided and angiographic-guided interventions for the rates of MACE and all-cause mortality. Moreover, the analysis showed that FFR-guided was associated with insignificantly decreased rates of MI (RR 0.77, 95% CI 0.51-1.16, $p=0.21$, $I^2=18\%$) and the number of revascularizations (RR 0.82, 95% CI 0.64-1.06, $p=0.12$, $I^2=0\%$). Finally, the average number of stents used per patient significantly favored the FFR-guided group (MD -0.16, 95% CI -0.24 to -0.07, $p=0.0003$, $I^2=93\%$). In conclusion, although FFR-guided did not have any benefit in decreasing MACE or all-cause mortality, it was associated with improved outcomes of MI, the number of revascularizations, and the average number of stents.

Keywords: FFR; Fractional flow reserve; Angiographic; PCI; CABG; Multivessel; Meta-analysis; Randomized

Introduction

Traditionally, Percutaneous Coronary Interventions (PCI) and Coronary Artery Bypass Graft (CABG) procedures are done under the guidance of angiography. A newer method is using the value of using Fractional Flow Reserve (FFR) in the indication for intervention. FFR is measured by a coronary pressure wire that can be entered via the femoral or radial arteries [1]. FFR for a coronary artery is defined as the ratio of maximal achievable blood flow to the theorized maximal blood flow without any stenosis. To determine this ratio mean distal coronary artery pressure is compared to the mean aortic pressure during maximal hyperemia [2]. The cut-off value to indicate which lesions are hemodynamically significant is 0.80 [2]. Since FFR is a measure of two easily obtained pressure, it eliminates the operator-

dependent evaluation of an angiographic image [2]. FFR also uses a lower dose of radiation and contrast medium as compared to coronary angiography [3]. Moreover, FFR accurately assesses the hemodynamic significance of coronary stenosis [1]. It is well known that CABG has short- and long-term advantages over PCI in patients with multivessel Coronary Artery Disease (CAD) [4]. Previous studies have demonstrated that FFR-guided PCI has beneficial outcomes in patients with multivessel CAD when compared to medical therapy and angiography-guided PCI [1,5-8]. Despite these studies, there is a gap of knowledge if FFR-guided CABG would still be preferred over FFR-guided PCI. In this updated meta-analysis, we aim to compare FFR-guided and angiographic-guided in studies that included patients with multivessel CAD that received PCI or CABG.



Methods

We conducted a comprehensive review of previous publications of all relevant studies from inception to 15 November 2021. We searched the electronic databases of PUBMED, EMBASE, COCHRANE, and Google scholar for RCTs. The search included the following keywords: “fractional flow reserve”, “FFR”, “angiographic”, “PCI”, “CABG”, “multivessel”, “randomized trial”. The inclusion criteria consisted of: (1) an RCT that compared FFR-guided and angiographic-guided interventions in patients with multivessel CAD, (2) the study reported more than 1 clinical or safety outcome, (3) human subjects, and (4) no restriction to language. Exclusion criteria were (1) follow-up data in < 90% of patients, (2) ongoing or irretrievable data, (3) no clinical outcome endpoint. This meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines (Figure 1). Two authors (RMP and ZQB) independently reviewed the search results, extracted potential articles, and assessed their eligibility. The Cochrane Collaboration risk-of-bias tool was used by 2 different authors (RMP and ZQB) to assess the quality of the included studies.

The primary outcome was the rate of Major Adverse Cardiovascular Events (MACE). The secondary outcomes were the rates of all-cause mortality, myocardial infarctions, revascularizations, and the average number of stents used per patient. We also collected baseline characteristics of the study and patients. Statistical analysis was conducted using Review Manager (RevMan), version 5.4 (The Cochrane Collaboration, Copenhagen, Denmark). The Mantel-Haenszel random-effects models were used to estimate the Risk Ratio (RR) and Mean Difference (MD) along with the corresponding 95% Confidence Intervals (CI). Two-sided p values of less than 0.05 were considered statistically significant. I² statistics were used to assess statistical heterogeneity.

Results

Five RCTs were included with a total of 2,288 patients and a median weighted follow-up period of 16.6 months (Figure 1) [9-13]. The characteristics of the included studies and patients are described in Tables 1 and 2. The definitions of the outcomes of MACE and MI for each of the included studies are reported in Table 3. There was no difference between FFR-guided and angiographic-guided interventions for the rates of MACE (RR 0.89, 95% CI 0.74-1.08, p=0.23, I²=0%) (Figure 2) and all-cause mortality (RR 1.22, 95% CI 0.53-2.78, p=0.64, I²=46%) (Figure 3). Moreover, the analysis showed

that FFR-guided was associated with insignificantly decreased rates of MI (RR 0.77, 95% CI 0.51-1.16, p=0.21, I²=18%) (Figure 4) and the number of revascularizations (RR 0.82, 95% CI 0.64-1.06, p=0.12, I²=0%) (Figure 5). Finally, the average number of stents used in the intervention significantly favored the FFR-guided group (MD -0.16, 95% CI -0.24 to -0.07, p=0.0003, I²=93%) (Figure 6).




Figure 1: The preferred reporting items for systematic reviews and meta-analyses (prisma) flow diagram.




Figure 2: Forest plot of the rate of major adverse cardiovascular events.




Figure 3: Forest plot of the rate of all-cause mortality.



Table 1: Study characteristics of included randomized controlled trials.

Study Name	First Author	Publication Year	Study Population	Intervention Group	Total Patients (n)	Latest Follow-Up Period (years)
FAME	Pijls	2010	Multivessel CAD, ST-elevation myocardial infarction with infarction at least 5 days before PCI	PCI	1005	1
FARGO	Thuesen	2018	Stable angina or stabilized NSTEMI and/or unstable angina were eligible if they had 1 or more study lesions planned for grafting by the CABG heart team	CABG	100	0.5
GRAFFITI	Toth	2019	Stable CAD or NSTEMI with significantly diseased left anterior descending artery or left main stem by angiography or by FFR and at least one additional major coronary artery with an angiographically intermediate stenosis (30-90% diameter stenosis by visual estimate)	CABG	172	1
-	Quintella	2019	Older than 21 years with stable multivessel CAD or at day 7 after acute coronary syndrome, with at least one moderate stenosis (>60%) without severe left ventricular dysfunction, and with non-invasive tests for ischemia	PCI	69	1
FUTURE	Rioufol	2021	CAD patients older than 18 years in stable or stabilized condition STEMI 24 hours after admission, with NSTEMI or unstable angina for over 12 hours and stable angina (maximum Canadian Cardiovascular Society class score I-III), and with atypical chest pain and positive noninvasive stress test	All-comers	927	2

Abbreviations: CABG: Coronary Artery Bypass Graft; CAD: Coronary Artery Disease; FFR: Fractional Flow Reserve; NSTEMI: Non-ST Elevation Myocardial Infarction; PCI: Percutaneous Coronary Intervention; STEMI: ST-Elevation Myocardial Infarction




Figure 4: Forest plot of the rate of myocardial infarction.




Figure 5: Forest plot of the rate of revascularization.






Figure 6: Forest plot of the average number of stents per patient.

Table 2: Baseline characteristics of included patients.

Study	Intervention Group	Number of Patients (n)	Total Lesions Per Patient (n)	Age (years)	Males	Smokers	Diabetes Mellitus	Dyslipidemia	Previous MI	Previous PCI
FAME 2010	PCI	509	2.8 ± 1.0	64.6 ± 10.3	384 (75)	138 (27)	123 (24)	366 (72)	187 (37)	146 (29)
		496	2.7 ± 0.9	64.2 ± 10.2	360 (73)	156 (32)	125 (25)	362 (74)	180 (36)	129 (26)
FARGO 2018	CABG	49	0.78 ± 0.12	66.4 ± 6.4	44 (88)	13 (27)	11 (22)	42 (86)	14 (29)	10 (20)
		48	0.77 ± 0.13	65.3 ± 8.8	44 (89)	8 (17)	11 (23)	36 (75)	10 (21)	9 (19)
GRAFFITI 2019	CABG	88	3 (3;4)	67 (62,72)	73 (83)	47 (53)	31 (35)	70 (80)	15 (17)	19 (22)
		84	3 (3;4)	67 (63,72)	66 (79)	35 (42)	33 (40)	66 (79)	5 (6)	12 (14)
Quintella et al. [11]	PCI	34	0.4 ± 0.5	62.7 ± 8.4	22 (65)	9 (26)	12 (35)	24 (71)	8 (24)	-
		53	1.0 ± 0.2	59.5 ± 9.4	25 (47)	10 (19)	12 (23)	26 (49)	7 (13)	-
FUTURE 2021	All-comers	460	3.5	65 ± 10	393 (85)	109 (24)	143 (31)	275 (60)	90 (20)	115 (25)
		467	3.5	66 ± 11	385 (82)	118 (26)	147 (32)	286 (61)	100 (21)	127 (27)

Values are reported as FFR | Angiographic. Units are reported as number (%), mean ± standard deviation, and median (IQR). Abbreviations: CABG, coronary artery bypass graft; FFR, fractional flow reserve; MI, myocardial infarction; PCI, percutaneous coronary intervention.

Discussion

This meta-analysis with 2,288 patients and a median weighted follow-up period of 16.6 months illustrated that in patients with multivessel CAD there was no difference in the rates of MACE or all-cause mortality. However, FFR-guided was insignificantly associated with decreased MI and number of revascularizations as well as significantly lower average number of stents. Although our results showed that the FFR-guided method did not improve the short-term outcomes except for rates of MI, it did improve the procedural characteristics. Moreover, studies have evaluated other procedural outcomes, such as significantly less contrast agent, shorter hospital stay, fewer materials used, and a cheaper incremental health care cost. There were also similar procedural times between both the FFR-guided and angiographic-guided groups [9-11]. Additionally, FFR has been proposed to help decide the most appropriate revascularization method [12]. The FAME 3 trial demonstrated that FFR-guided PCI in patients with multivessel disease was not noninferior to CABG in regards to a composite of death, myocardial infarction, stroke, or repeat revascularization. Otherwise, this trial illustrated decreased median values of time to procedure, procedure duration, and length of hospital stay. Although this trial included a total of 1,500 patients, it

was only conducted for 1 year and it has never been researched before [14].

The strengths of this meta-analysis include the short-term median weighted follow-up period of 16.6 months. The baseline characteristics of the patients in the included studies were grossly similar (Table 2). Additionally, based on the reported methods of the studies the technique of FFR was performed similarly.

Recently, Rioufol et al published the RCT FUTURE study that compared FFR-guided vs angiographic-guided in patients that received PCI or CABG. They showed that the FFR-guided arm did not result in a decreased risk of ischemic cardiovascular events, but did decrease the revascularization rates [14]. Of note, the initial RCTs included patients who exclusively received PCI [9,11] or CABG [10,12]. Therefore, FUTURE is the first study to randomly include all-comer patients. These findings were consistent with the previous studies, but the different inclusion criteria may have contributed to the level of heterogeneity seen in this meta-analysis. However, due to the limited number of studies in the current literature, we were unable to run a subgroup analysis to compare the different study populations of PCI, CABG, and all-comers. The other limitations of this meta-analysis were the small sample size and varying definitions of the clinical outcomes of MACE and MI (Table 3).

Table 3: Definitions of MACE and MI outcomes.

Study	Definition of MACE	Definition of MI
FAME 2010	Composite of all-cause mortality, myocardial infarction, or any repeat revascularization	Threefold or greater elevation of creatine kinase-myocardial band level or new Q-waves in greater than 2 contiguous leads of the electrocardiogram
FARGO 2018	Composite of all-cause mortality, nonprocedural myocardial infarction, any repeat revascularization, and stroke	Third definition used by the European Society of Cardiology, the American College of Cardiology, the American Heart Association, and the World Heart Federation
GRAFFITI 2019	Composite of all-cause mortality, myocardial infarction, stroke, or any revascularisation	-
Quintella et al. [11]	Composite of all-cause mortality and angina	-
FUTURE 2021	Composite of all-cause mortality, non-fatal myocardial infarction, unscheduled hospitalization leading to coronary revascularization, cerebrovascular accident	Nonfatal MI which are 1) symptoms of acute MI with ST-elevation or new left bundle branch block with an elevation of cardiac biomarkers, 2) elevation of cardiac biomarkers above 99th percentile of upper reference limit, or 3) evolution or appearance of pathological Q waves on electrocardiogram

Abbreviations: MACE: Major Adverse Cardiovascular Events; MI: Myocardial Infarction



Conclusion

FFR-guided PCI or CABG has improved procedural characteristics and similar short-term outcomes. Further studies should be conducted to confirm these findings, evaluate the outcomes in a long-term setting, and directly compare FFR-guided PCI vs CABG.

References

- Xaplanteris P, Fournier S, Pijls NHJ, Fearon WF, Barbato E, et al. (2018) FAME 2 Investigators. Five-Year Outcomes with PCI Guided by Fractional Flow Reserve. *N Engl J Med* 379(3): 250-259.
- Tebaldi M, Campo G, Biscaglia S (2015) Fractional flow reserve: Current applications and overview of the available data. *World J Clin Cases* 3(8): 678-681.
- Ntalianis A, Trana C, Muller O, Mangiacapra F, Peace A, et al. (2010) Effective radiation dose, time, and contrast medium to measure fractional flow reserve. *JACC Cardiovasc Interv* 3(8): 821-827.
- Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, et al. (2018) Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. *Lancet* 391(10124): 939-948.
- Bech GJ, De Bruyne B, Pijls NH, de Muinck ED, Hoorntje JC, et al. (2001) Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial. *Circulation* 103(24): 2928-2934.
- Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, et al. (2009) Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. *N Engl J Med* 360(3): 213-224.
- De Bruyne B, Fearon WF, Pijls NH, Barbato E, Tonino P, Piroth Z, et al. (2014) Fractional flow reserve-guided PCI for stable coronary artery disease. *N Engl J Med* 371(13): 1208-1217.
- Layland J, Oldroyd KG, Curzen N, Sood A, Balachandran K, et al. (2015) Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. *Eur Heart J* 36(2): 100-111.
- Pijls NH, Fearon WF, Tonino PA, Siebert U, Ikeno F, et al. (2010) Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. *J Am Coll Cardiol* 56(3): 177-184.
- Thuesen AL, Riber LP, Veien KT, Christiansen EH, Jensen SE, et al. (2018) Fractional Flow Reserve Versus Angiographically-Guided Coronary Artery Bypass Grafting. *J Am Coll Cardiol* 72(22):2732-2743.
- Quintella EF, Ferreira E, Azevedo VMP, Araujo DV, Sant'Anna FM, et al. (2019) Clinical Outcomes and Cost-Effectiveness Analysis of FFR Compared with Angiography in Multivessel Disease Patient. *Arq Bras Cardiol* 112(1): 40-47.
- Toth GG, De Bruyne B, Kala P, Ribichini FL, Casselman F, et al. (2019) Graft patency after FFR-guided versus angiography-guided coronary artery bypass grafting: the GRAFFITI trial. *EuroIntervention* 15(11): 999-1005.
- Rioufol G, Derimay F, Roubille F, Perret T, Motreff P, et al. (2021) Fractional Flow Reserve to Guide Treatment of Patients With Multivessel Coronary Artery Disease. *J Am Coll Cardiol* 78(19): 1875-1885.
- Fearon WF, Zimmermann FM, De Bruyne B, Piroth Z, van Straten AHM, et al. (2022) Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery. *N Engl J Med* 386(2): 128-137.

